BioSystems Highlights New iFOB Integral System at MedLab 2019

BioSystems S.A. (Barcelona, Spain) presented its analytical systems at MedLab Middle East 2019 held in Dubai, UAE, from February 4-7, 2019. MedLab Middle East 2019 attracted more than 19,610 unique visitors and the exhibition floor area housed 678+ exhibitors dedicated to sharing the most recent technology available in the IVD, and medical laboratory market. The MedLab Congress also enjoyed massive growth, welcoming more than 6,000 delegates to the multi-track conferences this year.

At MedLab Middle East 2019, BioSystems presented its new Fecal Occult Blood (iFOB) integral system, which provides a diagnostic solution for FOB testing. Colorectal cancer (CRC) is the third-most common cancer and the fourth-leading cause of cancer-related deaths in the world. CRC is treatable and preventable if it is detected in the early stages, with the detection of fecal occult blood being the key to preventing colorectal cancer.

BioSystems’ new iFOB system is comprised of an easy-to-use stool collection tube for easy sampling at the patient’s home or in the laboratory, an improved immunoturbidimetric assay in the form of a new and high sensitive antibody against human hemoglobin (no cross reaction with non-human Hb), an updated version of the company’s A15 analyzer with a new cap piercing function (no need to decap or recap samples tube after testing), and a dedicated software for fecal samples.

The iFOB system provides an accurate, reliable and safe method for FOB testing, making this test accessible to any kind of laboratory. In addition to FOB tests, BioSystems’ integral system can be updated with new fecal tests such as fecal Calprotectin, Transferrin and Helicobacter pylori, making the system a complete solution for stool samples analysis in the laboratory.